RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 68 - per page Next page
Order by
Small molecule platform capable of enhancing osteogenic differentiation of stem cells for the treatment of bone disorders.
Scientists at the forefront of regenerative medicine based at the Biomatcell Vinn Excellence Center of Biomaterials have identified this small molecule platform with these unique osteogenic differentiating properties and are now looking to develop them. More
Product enhancement of small and large molecules in a range of dosage forms
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms. More
Optimised pulmonary and nasal therapies using supercritical fluid (SCF) particle engineering
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Tackling challenges of poor solubility
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
Phase I Clinical Development of AEZS-130 (EP-1572): A Novel Peptidomimetic Growth Hormone Secretagogue
Phase I Clinical Development of AEZS-130 (EP-1572): A Novel Peptidomimetic Growth Hormone Secretagogue More
Method for Producing and Manipulating Intestinal Organotypic Culture
Method for Producing and Manipulating Intestinal Organotypic Culture More
Identification of NTproCNP: A Novel Biomarker to Predict Abnormal Growth
Identification of NTproCNP: A Novel Biomarker to Predict Abnormal Growth More
Methods to Clone PolyA mRNA (Differential Display): Insight into Novel Molecular Mechanisms in Development and Disease
Methods to Clone PolyA mRNA (Differential Display): Insight into Novel Molecular Mechanisms in Development and Disease More
Phase III Clinical Development of Octreotide (C2L) for the Treatment of Acromegaly
Phase III Clinical Development of Octreotide (C2L) for the Treatment of Acromegaly More
Development of a Novel Treatment for Mucositis: Completed Phase IIA Clinical Development of ATL-104
Development of a Novel Treatment for Mucositis: Completed Phase IIA Clinical Development of ATL-104 More
Displaying 1..10 of 68 - per page Next page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Musculoskeletal Disorders Pipeline Databook - November 2011
Nov 2011 - 7 pages - $3,835
Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis
Oct 2010 - 169 pages - $3,500
National Institute of Arthritis and Musculoskeletal and Skin Diseases – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
National Institute of Arthritis and Musculoskeletal and Skin Diseases – Developmental Therapeutics Review – Q4 2010
Dec 2010 - 84 pages - $500
Musculoskeletal Pain Global Clinical Trials Review, Q1, 2011
Mar 2011 - 34 pages - $1,000
National Institute of Neurological Disorders and Stroke – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
Lyme Disease Global Clinical Trials Review, Q1, 2011
Feb 2011 - 26 pages - $1,000
Myeloproliferative Disorders-Research Consortium – Developmental Therapeutics Review – Q4 2010
Dec 2010 - 22 pages - $500
Musculoskeletal Transplant Foundation - Medical Equipment - Deals and Alliances Profile
Mar 2011 - 16 pages - $250
Sleep Disorders - Pipeline Review, Q3 2011
Jul 2011 - 136 pages - $500
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us